Nordic Life Science Days 2014

Axcentua to participate at the Nordic Life Science Days 2014 & European Cancer Cluster, September 2014, Stockholm.

US Bio, June 2014, San Diego

Axcentua at US Bio, June 2014, San Diego. Please click the link below to download the presentation....

Clinical phase Ib patient enrollment completed

Enrollment completed in the phase Ib study of genistein-SSDH for the treatment of pancreatic cancer. All sixteen patients with locally advanced or metastatic pancreatic cancer has been enrolled and treated with genistein-SSDH in combination with gemcitabine.

Orphan designation granted for MPSIII

Orphan designation (EU/3/12/980) was granted by the European Commission to Axcentua Pharmaceuticals AB for genistein sodium salt dehydrate (genistein-SSDH) or AXP107-11 for the treatment of mucopolysaccharidosis type III (Sanfilippo syndrome).  

Axcentua granted patent on ten solid forms of genistein

Today a patent on ten different crystalline forms of genistein, including genistein-SSDH, was issued in South Africa patent No. 2011/05045 entitled “Crystalline forms of genistein, compositions comprising the same and uses thereof” with a patent term of 20 years from...

Axcentua granted US patent on Genistein-SSDH

The United States Patent and Trademark Office (USPTO) has issued Axcentua Pharmaceuticals the USPTO patent no 7,863,325 B2 entitled “Crystalline Genistein Sodium Salt Dihydrate”. The patent covers Axcentua’s novel crystalline composition of...

First patient enrolled in pancreatic cancer trial

Axcentua Pharmaceuticals AB today announced that the first patient has been enrolled in the clinical trial AXP-CT-001 (www.clinicaltrials.gov). The study is designed as a phase Ib/IIa study for the treatment of pancreatic cancer with AXP107-11 in combination with...

Approval from the Swedish Medical Product Agency

Axcentua Pharmaceuticals received approval from the Swedish Medical Product Agency to initiate a phase Ib/IIa clinical trial with its lead compound AXP107-11 or genistein-SSDH for the treatment of patients with pancreatic cancer.    ...